Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results for quarter ended March 31, 2026.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release and accompanying financial information attached as Exhibit 99.1
- Results announcement issued May 4, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $127.2M, up from $81.7M, driven by FILSPARI sales of $105.2M, up 88% year-over-year
- Record 993 IgAN patient starts and FDA-approved FSGS launch expand FILSPARI’s U.S. addressable population beyond 100,000 patients
- FSGS commercialization began immediately, with reimbursed treatments initiated within one week of April 13 approval
- Non-GAAP net income $4.1M versus $16.9M loss, while GAAP net loss narrowed to $37.1M from $41.2M
- Cash, equivalents and marketable securities $264.7M before $25M Mirum milestone received in April; HARMONY topline data expected 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.